Pharmaceutical - Par Pharmaceuticals

Filter

Current filters:

Par Pharmaceuticals

Popular Filters

US Appeals Court reverses 2012 decision on Lovaza, clearing way for generics

13-09-2013

Reversing a district court decision last year (The Pharma Letter May 30, 2012), the US Court of Appeals…

AmarinCardio-vascularGenericsGlaxoSmithKlineLegalLovazaNorth AmericaPar PharmaceuticalsPatentsPharmaceuticalTeva Pharmaceutical IndustriesVascepa

Par Pharma challenges FDA authority on off-label promotion

23-10-2011

In what may be a game-changer for drug companies, a court in the US District of Columbia has been asked…

Markets & MarketingMegace ESPar PharmaceuticalsPharmaceuticalRegulation

US antitrust body OKs Teva's acquisition of Cephalon, but with divestments

10-10-2011

Israel-based Teva Pharmaceutical Industries (Nasdaq: TEVA) says that the US Federal Trade Commission…

CephalonGenericsLegalMergers & AcquisitionsNorth AmericaPar PharmaceuticalsPharmaceuticalProvigilTeva Pharmaceutical Industries

Company Spotlight

ImmunoGen

ImmunoGen

Back to top